PDCD1 and cancer: Thus, seven ICIs are currently in clinical use for cancer therapy, ipilimumab—targeting CTLA-4—pembrolizumab and nivolumab—targeting PD-1—and atezolizumab, avelumab, durvalumab, and cemiplimab, targeting PD-L1.